Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10013412HBVENSG00000133019.12protein_codingCHRM3NoNo1131P20309
TVIS10013413HBVENSG00000133019.12protein_codingCHRM3NoNo1131P20309
TVIS10013414HBVENSG00000133019.12protein_codingCHRM3NoNo1131P20309
TVIS10013415HBVENSG00000133019.12protein_codingCHRM3NoNo1131P20309
TVIS10013416HBVENSG00000133019.12protein_codingCHRM3NoNo1131P20309
TVIS10013417HBVENSG00000133019.12protein_codingCHRM3NoNo1131P20309
TVIS10013418HBVENSG00000133019.12protein_codingCHRM3NoNo1131P20309
TVIS10013419HBVENSG00000133019.12protein_codingCHRM3NoNo1131P20309
TVIS10013420HBVENSG00000133019.12protein_codingCHRM3NoNo1131P20309
TVIS10019801HBVENSG00000133019.12protein_codingCHRM3NoNo1131P20309
TCGA Plot Options
Drug Information
GeneCHRM3
DrugBank IDDB00496
Drug NameDarifenacin
Target IDBE0000045
UniProt IDP20309
Regulation Typeantagonist
PubMed IDs20395537; 19416629; 18046909; 11752352
CitationsBharucha AE, Ravi K, Zinsmeister AR: Comparison of selective M3 and nonselective muscarinic receptor antagonists on gastrointestinal transit and bowel habits in humans. Am J Physiol Gastrointest Liver Physiol. 2010 Jul;299(1):G215-9. doi: 10.1152/ajpgi.00072.2010. Epub 2010 Apr 15.@@Bozkurt TE, Sahin-Erdemli I: M(1) and M(3) muscarinic receptors are involved in the release of urinary bladder-derived relaxant factor. Pharmacol Res. 2009 May;59(5):300-5. doi: 10.1016/j.phrs.2009.01.013. Epub 2009 Feb 5.@@Jha S, Parsons M: Treatment of overactive bladder in the aging population: focus on darifenacin. Clin Interv Aging. 2006;1(4):309-16.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
GroupsApproved; Investigational
Direct ClassificationDiphenylmethanes
SMILESNC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1
Pathways
PharmGKBPA164774901
ChEMBLCHEMBL1346